Table 2 Correlation of ENS-653 expression of with clinicopathologic variables of PTC patients
From: LncRNA ENST00000539653 acts as an oncogenic factor via MAPK signalling in papillary thyroid cancer
Characteristics | ENS-653 expressiona | P-value | |
|---|---|---|---|
Low | High | ||
(n = 22) | (n = 64) | ||
Age (years) | 51.5 ± 13.2 | 57.2 ± 13.3 | 0.088* |
Gender [n(%)] | 0.833† | ||
Female | 16 (72.7) | 48 (75.0) | |
Male | 6 (27.3) | 16 (25.0) | |
Histological subtypes [n(%)] | 1.000§ | ||
Classic | 21 (95.5) | 62 (96.9) | |
Follicular | 1 (4.5) | 2 (3.1) | |
Tumor size [n(%)] | < 0.001† | ||
< 2 cm | 14 (63.6) | 15 (23.4) | |
≥2 cm | 8 (36.4) | 49 (76.6) | |
Extrathyroidal extension [n(%)] | 2 (9.1) | 7 (10.9) | 1.000§ |
Multifocality [n(%)] | 6 (27.3) | 17 (26.6) | 0.948† |
Coexistent HTb [n(%)] | 5 (22.7) | 15 (23.4) | 0.946† |
T Stage [n(%)] | 0.856§ | ||
T1 | 14 (22.7) | 15 (17.2) | |
T2 | 7 (72.7) | 46 (78.1) | |
T3 | 1 (4.5) | 2 (3.1) | |
T4 | 0 (0.0) | 1 (1.6) | |
N1 [n(%)] | 9 (40.9) | 27 (42.2) | 0.916† |
M1 [n(%)] | 0 (0.0) | 4 (6.2) | 0.568§ |
Clinical Stage [n(%)] | 0.001§ | ||
I | 11 (50.0) | 8 (12.5) | |
II | 2(9.1) | 26(40.6) | |
III | 8(36.4) | 25(39.1) | |
IV | 1 (4.5) | 5 (7.8) | |